Guardant Health, Inc. and its research collaborators presented results from the largest study to date evaluating circulating tumor DNA (ctDNA) in colon cancer prior to chemotherapy. The study demonstrated the Guardant Reveal test's ability to stratify the risk of disease recurrence and overall survival, informing treatment decisions after surgery.
Data from the phase III NCCTG N0147 trial, involving over 2,000 patients with stage III colon cancer, showed that ctDNA detected post-surgery and pre-adjuvant therapy is a strong predictor of recurrence and poorer survival. Patients with detectable ctDNA had a 2.5 times higher risk of recurrence and a 2.8 times higher risk of death.
Frank Sinicrope, MD, principal investigator, stated that post-surgical ctDNA analysis improves recurrence prediction over standard staging criteria, which may guide patient management. Helmy Eltoukhy, Guardant Health co-CEO, affirmed the test's ability to identify high-risk patients who would benefit most from adjuvant therapy, improving patient outcomes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.